Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Study identifier:MB001-078

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Medical condition

Diabetes mellitus type 2

Phase

Healthy volunteers

Study drug

Exenatide

Sex

All

Actual Enrollment

1711

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Feb 2009

Primary Completion Date: 01 Mar 2014

Study Completion Date: 01 Mar 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Local Institution

Seoul, Republic of Korea, 110-756

Arms	Assigned Interventions
Group1:Type 2 diabetic patients treated with Exenatide therapy Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label	-

"There is no result for the study"

Documents available

BMS Clinical Trials Disclosure
Download
Investigator Inquiry form
Download
FDA Safety Alerts and Recalls
Download
CSR_Synopsis_MB001-078.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

For Site information please email:

Clinical.Trials@bms.com

Contact Backup

First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time

Investigators

Principal Investigator

Bristol-Myers Squibb

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Local Institution

Documents available

BMS Clinical Trials Disclosure

Investigator Inquiry form

FDA Safety Alerts and Recalls

CSR_Synopsis_MB001-078.pdf

Trial Results Summaries

Contacts

Contact

Contact Backup

Investigators

Principal Investigator